FOXC2 and hepatocellular carcinoma: Actually, resveratrol has been reported to suppress the viability of HCC cells [35–37]; therefore, the administration of resveratrol in patients with clinical HCC may be a good therapeutic candidate to overcome HCC aggressiveness via targeting FOXC2.